Shares of ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $3.49, but opened at $3.64. ImmunityBio shares last traded at $3.71, with a volume of 929,108 shares changing hands.
Analysts Set New Price Targets
Separately, Piper Sandler decreased their target price on ImmunityBio from $6.00 to $4.75 and set a "neutral" rating for the company in a research note on Monday, August 19th.
Read Our Latest Research Report on IBRX
ImmunityBio Trading Down 0.9 %
The business's fifty day moving average is $3.69 and its 200 day moving average is $5.38. The firm has a market capitalization of $2.39 billion, a P/E ratio of -3.20 and a beta of 1.02.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its earnings results on Monday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.03). The firm had revenue of $1.05 million during the quarter, compared to the consensus estimate of $2.53 million. As a group, sell-side analysts predict that ImmunityBio, Inc. will post -0.86 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. Bleakley Financial Group LLC acquired a new stake in ImmunityBio during the 1st quarter valued at $58,000. Lazard Asset Management LLC raised its position in ImmunityBio by 102.6% during the first quarter. Lazard Asset Management LLC now owns 13,019 shares of the company's stock valued at $68,000 after buying an additional 6,593 shares during the period. Axxcess Wealth Management LLC purchased a new stake in ImmunityBio in the 1st quarter worth about $85,000. Algert Global LLC acquired a new stake in ImmunityBio during the 2nd quarter worth about $86,000. Finally, Brookstone Capital Management acquired a new position in shares of ImmunityBio in the 1st quarter valued at about $100,000. 8.58% of the stock is owned by hedge funds and other institutional investors.
About ImmunityBio
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Featured Articles
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
